GENERAL, O. Reg. 201/96

Section 12

Cite as GENERAL, O. Reg. 201/96, s. 12 · current to November 11, 2026 · consolidated from July 1, 2026 · read from e-Laws on November 16, 2026

The text

(1) A strength and dosage form of a drug product shall not be designated as a listed drug product unless the manufacturer of the drug product submits to the executive officer, (a) either, (i) evidence that Health Canada has approved the product for sale in Canada and, subject to subsection (2), a copy of the product monograph approved by Health Canada, or (ii) evidence that an application has been made to Health Canada to approve the product for sale in Canada, and evidence satisfactory to a panel of experts established for the purpose that the product meets at least one of the following criteria: A. The product is a new chemical entity that is effective for the treatment of an immediately life-threatening disease or other serious disease for which it offers substantial improvements on significant outcomes, including improved efficacy, safety and tolerability and quality of life over other available drug therapies in Canada, or for which no treatment or no other effective drug therapy is currently available in Canada. B. The product is a new chemical entity that would have, if designated as a listed drug product, the effect of saving or creating efficiencies for the Government of Ontario, an average of at least $2,500,000 per year for the first three years the product is marketed in Ontario. C. The product is a new chemical entity that would have, if designated as a listed drug product, the effect of saving the Ontario Drug Benefit Program an average of at least $250,000 per year for the first three years the product is marketed in Ontario; (b) a letter authorizing the executive officer to gain access to all information with respect to the product in the possession of Health Canada, the Patented Medicine Prices Review Board established under section 91 of the Patent Act (Canada), the government of any province or territory in Canada or the Canadian Agency for Drugs and Technologies in Health and authorizing the executive officer to disclose any information with respect to the product in the possession of the Ministry to Health Canada, the Patented Medicine Prices Review Board, the government of a province or territory in Canada or the Canadian Agency for Drugs and Technologies in Health; (c) an estimate of the net costs to the Ontario Drug Benefit Program in a three-year period; (d) the proposed drug benefit price of the product; (e) evidence that the manufacturer is able to supply the product at the proposed drug benefit price in a quantity sufficient to meet the anticipated demand for the product; (f) certification in writing that no rebate as defined in subsection 11.5 (15) of the Act has been provided to a person listed in subsection 11.5 (1) of the Act with respect to the product contrary to the Act since Health Canada approved the product for sale in Canada; (g) Revoked: O. Reg. 27/97, s. 1 (3). (h) clinical studies and, if available, other clinical evidence of the product’s therapeutic effectiveness or efficacy and of the product’s safety, including any information that relates to adverse drug reactions and any existing clinical studies comparing the product’s therapeutic effectiveness or efficacy and the product safety to that of other products or treatments; and (i) evidence demonstrating the benefit of the product in relation to the cost of the product and to alternative products or treatments. O. Reg. 201/96, s. 12 (1); O. Reg. 27/97, s. 1 (1-3); O. Reg. 495/00, s. 2 (1, 2); O. Reg. 338/03, s. 1; O. Reg. 645/05, s. 2; O. Reg. 459/06, s. 7 (1-4); O. Reg. 320/07, s. 2 (1); O. Reg. 436/19, s. 2 (1). (2) If Health Canada has not approved a product monograph for a drug product, the manufacturer of the drug product may, instead of submitting a copy of the product monograph as required under clause (1) (a), submit to the executive officer the following information: 1. Pharmaceutical information. 2. Information with respect to the product’s clinical pharmacology. 3. Information as to the product’s indications and clinical use. 4. A list of any contra-indications, warnings or precautions in the use of the product and of possible adverse reactions to its use. 5. A list of symptoms of an overdose of the product and information as to the treatment of an overdose. 6. Information with respect to the dosage and administration of the product. 7. Information regarding the availability of dosage forms for each strength of the product marketed in Canada. O. Reg. 201/96, s. 12 (2); O. Reg. 495/00, s. 2 (3); O. Reg. 459/06, s. 7 (5). (2.1) Clauses (1) (c), (h) and (i) do not apply to the manufacturer of a drug product if the executive officer is satisfied that the product is clinically effective and has a low risk for inappropriate utilization if designated as a listed drug product for the indication or indications in the submission and, (a) the executive officer has, since December 31, 2008 or earlier, made the Act apply in respect of the supplying of the drug in accordance with section 16 of the Act for the indication or indications in the submission; or (b) the executive officer has, since December 31, 2008 or earlier, made the Act apply in respect of the supplying of the drug in accordance with section 16 of the Act for a different indication or indications, and the Canadian Agency for Drugs and Technologies in Health has issued a positive funding recommendation in respect of the drug product for the indication or indications in the submission. O. Reg. 320/16, s. 1. (2.2) Clauses (1) (h) and (i) do not apply to the manufacturer of a biosimilar product if the executive officer is satisfied that the product is safe, therapeutically effective or efficacious, and appropriate for public funding, having regard to, (a) its approval for sale in Canada by Health Canada; (b) the availability or funding of other drug products that treat the same or similar indications, including the original biologic product; and (c) any other information available to the executive officer. O. Reg. 436/19, s. 2 (2). (2.3) Clause (1) (h) does not apply to a drug product that is not a new drug as defined in the Food and Drug Regulations made under the Food and Drugs Act (Canada) if the executive officer is satisfied that the product is safe, therapeutically effective or efficacious, and appropriate for public funding, having regard to, (a) its approval for sale in Canada by Health Canada; and (b) any other information available to the executive officer. O. Reg. 84/24, s. 1. (3) A manufacturer may satisfy the condition set out in clause (1) (h) for a strength of a drug product by submitting the clinical evidence referred to in clause (1) (h) for another strength of the same dosage form of the drug product, if the evidence is sufficient for the purposes of evaluating the therapeutic effectiveness or efficacy and the safety of both the strengths of the dosage form of the product. O. Reg. 201/96, s. 12 (3). (3.1) A manufacturer may satisfy the condition set out in clause (1) (h) for a format of a drug product by submitting the clinical evidence referred to in clause (1) (h) for another format of the drug product, if the evidence is sufficient for the purposes of evaluating the therapeutic effectiveness or efficacy and safety of both the formats of the product. O. Reg. 495/00, s. 2 (4). (4) A manufacturer may satisfy the condition set out in clause (1) (h) for a drug product by submitting to the executive officer the clinical evidence referred to in clause (1) (h) with respect to another product and submitting evidence that satisfies the executive officer that the two products are bioequivalent. O. Reg. 201/96, s. 12 (4); O. Reg. 495/00, s. 2 (5); O. Reg. 459/06, s. 7 (6). (5) Subsection (4) does not apply if the drug product that the manufacturer seeks to have designated is the drug product of a drug for which there exists a listed drug product. O. Reg. 201/96, s. 12 (5). (5.1) Clauses (1) (h) and (i) do not apply to a generic line extension drug product if the executive officer is satisfied that the product is safe, therapeutically effective or efficacious, and appropriate for public funding, having regard to, (a) its approval for sale in Canada by Health Canada; and (b) any other information available to the executive officer. O. Reg. 436/19, s. 2 (3). (5.2) A manufacturer is exempt from complying with clauses 1 (a), (e), (h) and (i) where the executive officer is satisfied that, (a) there is a shortage of a listed drug product, or a drug to which the executive officer has made the Act apply under section 16 of the Act, with the same or similar active ingredients or therapeutic use as the drug product; and (b) the exemption is in the public interest having regard to the urgency of the situation, significant patient safety or access concerns and the cost impact to the Government of Ontario, as well as to the safety and therapeutic effectiveness or efficacy of the drug product. O. Reg. 436/19, s. 2 (4). (6) Subsection (1) does not apply to a drug product that is proposed to be designated as an interchangeable product under the Drug Interchangeability and Dispensing Fee Act. O. Reg. 201/96, s. 12 (6); O. Reg. 355/08, s. 2. (7) If required by the executive officer, the manufacturer of the product shall enter into an agreement with the executive officer that specifies any volume discount or other amount that may be payable by the manufacturer to the Minister of Finance, and shall agree that the executive officer may make public the following information, and that information only, with respect to the agreement: 1. The name of the manufacturer. 2. The subject-matter of the agreement. 3. The fact of entering into or terminating the agreement. O. Reg. 459/06, s. 7 (7). (8) Despite subclause (1) (a) (ii), but subject to subsection (6), a product may not be designated as a listed drug product until evidence that satisfies subclause (1) (a) (i) is also received. O. Reg. 459/06, s. 7 (7). (8.1) It is a condition of being listed as a listed drug product that the manufacturer must not have provided a rebate as defined in subsection 11.5 (15) of the Act to a person listed in subsection 11.5 (1) of the Act with respect to the product contrary to the Act since Health Canada approved the product for sale in Canada. O. Reg. 320/07, s. 2 (2). (9) A strength and dosage form of a drug product that contains oxycodone as the only active ingredient and that is a long-acting product that has been formulated in a solid dosage form for oral administration shall not be designated as a listed drug product unless the following conditions are met: 1. There must be evidence satisfactory to the executive officer that the drug product exhibits one or more physiochemical properties that, when compared to drugs without the property or properties, make the drug product, i. significantly more difficult to alter, break, crush, chew, dissolve or otherwise manipulate in such a way that it could be misused, abused or put to an intended use that is different than the use for which it is prescribed, or ii. significantly less effective and less likely to be misused, abused or put to an intended use that is different than the use for which it is prescribed, if the product is altered, broken, crushed, chewed, dissolved or otherwise manipulated. 2. The evidence referred to in paragraph 1 must be demonstrated by, i. in vitro testing, ii. in vivo testing, iii. another form of testing of equivalent reliability, or iv. a combination of any of the forms of testing mentioned in subparagraphs i to iii. O. Reg. 20/13, s. 2. (10) In clause (1) (a), “Government of Ontario” includes all ministries of the Government of Ontario, all programs and agencies funded by the Government of Ontario and all agencies that are established by Ontario statute or regulation but are not necessarily funded by the Government of Ontario. O. Reg. 459/06, s. 7 (7).
Read the GENERAL on e-Laws ↗

Made under Ontario Drug Benefit Act, R.S.O. 1990, c. O.10.